My evidence-based, formal appeal to twitter, July 27, 2022: “I was simply interpreting scientific data, and engaging in debate as twitter’s policy encourages.”

This amounts to harassment by twitter.

Nothing I said/wrote was demonstrably false—in fact as I outline below, what I wrote was entirely evidence-based. I was simply interpreting scientific data, and engaging in debate as twitter’s policy encourages.

Pediatric data, 6 month to 11 years old children, substantiating my comment, “The only RCT [randomized, controlled trial] data we have from children reveals zero hospitalizations prevented by vaccination”:

A June 15, 2022 FDA filing document reported the following data on “severe covid-19”, including hospitalized covid-19, from Pfizer’s mRNA vaccine randomized placebo-controlled trial (https://www.fda.gov/media/159195/download)  in 6-month to 23 month old (<5 year old) children: “Among all COVID-19 cases accrued from Dose 1 through the data cutoff of April 29, 2022, 1 placebo recipient 6-23 months of age and 7 participants 2-4 years of age (6 BNT162b2 recipients and 1 placebo recipient) met the protocol-specified criteria for severe COVID-19 during both blinded and open-label follow-up. Only one of these severe COVID-19 cases (in a BNT162b2 recipient 99 days post-Dose 2) resulted in hospitalization

The Pfizer covid-19 vaccine randomized, placebo-controlled trial (https://www.fda.gov/media/153409/download) in 5 to 11 year-olds recorded zero cases of severe covid-19 in either the vaccinated or placebo group, despite recruiting ~20% with comorbidities.

Adult (18+ year old) data substantiating my comment, “The RCT data from adults shows more SAEs (serious adverse events) caused by [Covid-19] vax [vaccination] than C19 [Covid-19] hosps [hospitalizations] prevented.”

Fraiman et al (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4125239)  performed a secondary analysis of serious adverse events reported in the placebo-controlled, phase III randomized clinical trials of Pfizer and Moderna mRNA COVID-19 vaccines (NCT04368728 and NCT04470427), focusing their analysis on potential serious adverse events (SAE) of special interest identified by the Brighton Collaboration. For each trial, blinded SAE tables were prepared. Using the blinded SAE tables, two clinician reviewers (JF and JE) independently judged whether each SAE type was an AESI. They reported, “Combined, the mRNA vaccines were associated with an absolute risk increase of serious adverse events of special interest of 12.5 per 10,000 (95% CI 2.1 to 22.9). The excess risk of serious adverse events of special interest surpassed the risk reduction for COVID-19 hospitalization relative to the placebo group in both Pfizer and Moderna trials (2.3 and 6.4 per 10,000 participants, respectively).”

 

 

 

Comments are closed.